|Description||CH5138303 is a novel and potent Hsp90 inhibitor. CH5138303 showed high binding affinity for N-terminal Hsp90α (Kd=0.52nM) and strong in vitro cell growth inhibition against human cancer cell lines (HCT116 IC50=0.098μM, NCI-N87 IC50=0.066μM) and also displayed high oral bioavailability in mice (F=44.0%) and potent antitumor efficacy in a human NCI-N87 gastric cancer xenograft model (tumor growth inhibition=136%).|
|Brife Description||CH5138303 is an orally available Hsp90 inhibitor with Kd of 0.48 nM.|
|Appearance||White solid powder|
|Synonyms||CH-5138303; CH 5138303|
|Solubility||DMSO: 83 mg/mL|
|Storage||3 years -20oC powder, 6 months-80oC in solvent.|
Alvespimycin hydrochloride is the hydrochloride salt of alvespimycin, an analogue of the antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds...
Herbimycin A is an ansamycin antibiotic that acts as a Src family kinase inhibitor. Binds to the SH domain and inhibits the activity of p60v-src and p210BCR-ABL...
PF-04929113, also known as SNX-5422; is a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although t...
Triolimus is a composed of a micelle containing the drugs rapamycin, 17-AAG, and paclitaxel, which act synergistically to inhibit tumor growth
C086 inhibits Hsp90 and BCR-ABL, resulting in decreased proliferation of tumor cells, including imatinib-resistant cells.
VER-155008 is an adenosine-derived inhibitor of heat shock protein 70 (Hsp70; IC50 = 0.5 µM) that is selective over Hsp90.It targets the nucleotide-binding doma...
Luminespib, also known as AUY-922 (or NVP-AUY922), is a derivative of 4,5-diarylisoxazole and a third-generation heat shock protein 90 (Hsp90) inhibitor with po...
Bnlm is a Grp94 selective inhibitors.